Tetraethyl orthosilicate hydrolyzed | CAS:68412-37-3

We serve Tetraethyl orthosilicate hydrolyzed CAS:68412-37-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Tetraethyl orthosilicate hydrolyzed

Product Name: Tetraethyl orthosilicate hydrolyzed
Other Name: Silicic acid tetraethyl ester hydrolyzed
CAS No: 68412-37-3
MF: C8H20O4Si
MW: 208.32700
Density: 1.06 g/cm3
Boiling point: 160ºC
Melting point: -60ºC
Flash point: 63ºC
UN Number: UN1993
UN Proper Shipping Name: FLAMMABLE LIQUID, N.O.S.
Transport hazard class: 3.2
Packing group: III
 
Specification
Appearance: Colorless transparent liquid
Assay: ≥99.0%
 
Application
Be hydrolyzed to form silicon dioxide (silica).
Crosslinkers in silicone rubber systems.
Drying agents in sealing compositions.
Inorganic binder for refractory fillers and pigments.
Coating material for pigments, fibers and other surfaces.
Chemical intermediate.
 
Package: 210L Iron Drum: 200kg/drum or 1000L IBC Container: 1000kg/container, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like Tetraethyl orthosilicate hydrolyzed chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Silicic acid tetraethyl ester hydrolyzed physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Silicic acid tetraethyl ester hydrolyzed Use and application,Silicic acid tetraethyl ester hydrolyzed technical grade,usp/ep/jp grade.


Related News: Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed.2,6-dimethylpyridin-3-amine manufacturer Singapore, Australia, New Zealand, and the United States have banned all foreign nationals traveling from China from entering the country.L-Ornithine Monohydrochloride supplier Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”3-Amino-6-bromopyridine vendor With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.